NasdaqGS:NGM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has NGM Biopharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NGM has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.7%

NGM

-5.6%

US Pharmaceuticals

-5.3%

US Market


1 Year Return

29.2%

NGM

1.7%

US Pharmaceuticals

10.4%

US Market

Return vs Industry: NGM exceeded the US Pharmaceuticals industry which returned 1.5% over the past year.

Return vs Market: NGM exceeded the US Market which returned 12% over the past year.


Shareholder returns

NGMIndustryMarket
7 Day1.7%-5.6%-5.3%
30 Day7.0%-5.6%-2.1%
90 Day-5.2%-5.2%1.7%
1 Year29.2%29.2%4.3%1.7%12.9%10.4%
3 Yearn/a19.1%10.3%34.3%25.4%
5 Yearn/a30.8%15.7%73.7%54.3%

Price Volatility Vs. Market

How volatile is NGM Biopharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NGM Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NGM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NGM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NGM is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: NGM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NGM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NGM is overvalued based on its PB Ratio (4x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is NGM Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-18.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NGM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NGM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NGM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NGM's revenue (5.1% per year) is forecast to grow slower than the US market (10% per year).

High Growth Revenue: NGM's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NGM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has NGM Biopharmaceuticals performed over the past 5 years?

-67.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NGM is currently unprofitable.

Growing Profit Margin: NGM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NGM is unprofitable, and losses have increased over the past 5 years at a rate of 67.9% per year.

Accelerating Growth: Unable to compare NGM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NGM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.7%).


Return on Equity

High ROE: NGM has a negative Return on Equity (-23.77%), as it is currently unprofitable.


Next Steps

Financial Health

How is NGM Biopharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: NGM's short term assets ($322.6M) exceed its short term liabilities ($33.7M).

Long Term Liabilities: NGM's short term assets ($322.6M) exceed its long term liabilities ($12.4M).


Debt to Equity History and Analysis

Debt Level: NGM is debt free.

Reducing Debt: NGM has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NGM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NGM has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 32.1% each year.


Next Steps

Dividend

What is NGM Biopharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NGM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NGM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NGM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NGM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

David Woodhouse (49 yo)

2yrs

Tenure

US$2,092,150

Compensation

Dr. David J. Woodhouse, Ph.D. served as Acting Chief Financial Officer of NGM Biopharmaceuticals, Inc. since September 2018 until July 13, 2020. He served as the Chief Financial Officer of NGM Biopharmaceu ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD2.09M) is about average for companies of similar size in the US market ($USD2.96M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
William Rieflin
Executive Chairman of the Board of Directors2yrsno data4.03%
$ 48.0m
David Woodhouse
CEO & Director2yrsUS$2.09m0.12%
$ 1.4m
Jin-Long Chen
Founder12.75yrsUS$1.92m1.7%
$ 20.3m
Aetna Trombley
Consultant0.58yrUS$1.29m0%
$ 0
Siobhan Mangini
CFO and Principal Financial & Accounting Officer0.25yrno datano data
Valerie Pierce
Senior VP1yrno datano data
Brian Muma
Vice President of Human Resources0.17yrno datano data
Hui Tian
Senior Vice President of Researchno datano datano data
Alex DePaoli
Chief Translational Officer & Senior VPno datano datano data
Wenyan Shen
Senior Vice President of Biologics and CMCno datano datano data
Hsiao Lieu
Chief Medical Officer & Senior VP1.58yrsno data0.00026%
$ 3.1k

1.3yrs

Average Tenure

50yo

Average Age

Experienced Management: NGM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
William Rieflin
Executive Chairman of the Board of Directors2yrsno data4.03%
$ 48.0m
David Woodhouse
CEO & Director2yrsUS$2.09m0.12%
$ 1.4m
Jin-Long Chen
Founder12.75yrsUS$1.92m1.7%
$ 20.3m
Mark Leschly
Independent Director12.75yrsUS$221.62k0%
$ 0
McHenry Tichenor
Independent Director10.58yrsUS$241.12k0%
$ 0
David Goeddel
Lead Independent Director2yrsUS$240.37k0.28%
$ 3.3m
Michael Brown
Chairman of the Scientific Advisory Boardno datano datano data
Joseph Goldstein
Member of the Scientific Advisory Boardno datano datano data
David Schnell
Independent Director12.75yrsUS$225.37k0%
$ 0
Robert Schreiber
Member of Scientific Advisory Boardno datano datano data
Suzanne Hooper
Independent Director2.17yrsUS$730.35k0.010%
$ 121.4k
Michael Fischbach
Member of Scientific Advisory Boardno datano datano data

6.4yrs

Average Tenure

60yo

Average Age

Experienced Board: NGM's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.


Top Shareholders

Company Information

NGM Biopharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NGM Biopharmaceuticals, Inc.
  • Ticker: NGM
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.193b
  • Shares outstanding: 68.79m
  • Website: https://www.ngmbio.com

Number of Employees


Location

  • NGM Biopharmaceuticals, Inc.
  • 333 Oyster Point Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NGMNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2019
0IKDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2019

Biography

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthal ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/31 00:27
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.